NCT02660931

Brief Summary

This proposal will incorporate statistical models developed by the investigators to predict risk for acute kidney injury into our electronic medical record system, enabling an alert to notify providers of the risk status. Pediatric inpatients will be randomly assigned to be in the intervention group, for whom the notification will be implemented, or in the control group, who will receive usual care (no notification). The investigators believe the notification will increase appropriate screening for acute kidney injury and reduce the severity of acute kidney injury in the intervention group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12,108

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 21, 2016

Completed
10 months until next milestone

Study Start

First participant enrolled

November 1, 2016

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2017

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
Last Updated

April 3, 2019

Status Verified

April 1, 2019

Enrollment Period

1 year

First QC Date

January 18, 2016

Last Update Submit

April 1, 2019

Conditions

Keywords

Pediatrics

Outcome Measures

Primary Outcomes (1)

  • Number of Serum Creatinine Tests Ordered

    Measure of efficacy of the clinical decision support to lead to increased screening for acute kidney injury.

    Admission through Discharge (approximately 2 days to 1 week)

Secondary Outcomes (4)

  • Length of Stay (days)

    Admission through Discharge (approximately 2 days to 1 week)

  • Acute Kidney Injury Severity (as measured by Kidney Disease Improving Global Outcomes [KDIGO] stage 1, 2 or 3)

    Admission through Discharge (approximately 2 days to 1 week)

  • In-hospital Mortality

    Admission through Discharge (approximately 2 days to 1 week)

  • Renal Replacement Therapy (number requiring RRT)

    Admission through Discharge (approximately 2 days to 1 week)

Study Arms (2)

AKI Risk Notification

EXPERIMENTAL

Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.

Other: AKI Risk Notification

Usual Care

NO INTERVENTION

These patients will receive usual clinical care, with no acute kidney injury risk notification.

Interventions

When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.

AKI Risk Notification

Eligibility Criteria

Age28 Days - 21 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • All admissions to the pediatric intensive care unit or pediatric wards at the Monroe Carell Junior Children's Hospital at Vanderbilt

You may not qualify if:

  • Prior diagnosis of chronic renal disease, including dialysis and transplant
  • Admission to the Neonatal Intensive Care Unit during the current admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Monroe Carell Jr. Children's Hospital at Vanderbilt

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Acute Kidney InjuryKidney Diseases

Condition Hierarchy (Ancestors)

Renal InsufficiencyUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Sara L Van Driest, MD, PhD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 18, 2016

First Posted

January 21, 2016

Study Start

November 1, 2016

Primary Completion

November 1, 2017

Study Completion

November 1, 2018

Last Updated

April 3, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations